Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALDIPETE-T is an adsorbed combination vaccine developed and manufactured by the Institute of Virology, Vaccines and Sera Torlak in Serbia. It is indicated for active immunization against pertussis (whooping cough), diphtheria, and tetanus. The vaccine formulation consists of diphtheria and tetanus toxoids along with pertussis components that are adsorbed onto an aluminum-based adjuvant to enhance the immune response. By introducing these inactivated toxins and bacterial components, the vaccine stimulates the production of protective antibodies and cellular immunity, providing long-term protection against infection and the systemic effects of the toxins produced by *Corynebacterium diphtheriae* and *Clostridium tetani*.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ALDIPETE-T.